Perrigo Company plc (PRGO)

Market Cap	2.10B -29.0%
Revenue (ttm)	4.14B -4.2%
Net Income	-1.73B
EPS	-12.49
Shares Out	138.77M
PE Ratio	n/a
Forward PE	6.58
Dividend	$1.16 (7.68%)
Ex-Dividend Date	Aug 28, 2026

Volume	2,320,963
Open	15.21
Previous Close	15.42
Day's Range	14.90 - 15.43
52-Week Range	9.23 - 22.65
Beta	0.60
Analysts	Buy
Price Target	16.50 (+9.27%)
Est. Earnings	Nov 4, 2026

About PRGO

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pai...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Dec 16, 1991
• Employees: 8,100
• Stock Exchange: NYSE
• Ticker Symbol: PRGO
• Website: https://www.perrigo.com

Financial Performance

In 2025, Perrigo Company's revenue was $4.25 billion, a decrease of -2.75% compared to the previous year's $4.37 billion. Losses were -$1.43 billion, 729.7% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for PRGO stock is "Buy." The 12-month stock price target is $16.5, which is an increase of 9.27% from the latest price.

Price Target

$16.5

(9.27% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 28, 2026

Data Sources Report a data error